22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › KRYSTAL BIOTECH INC. › 2024-2025

KRYSTAL BIOTECH INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and KRYSTAL BIOTECH INC.’s Form 8-K, filed May 19, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 306Asset managers, any item
  • 2,142Fund votes
  • May 16, 2025Meeting date

Results at a glance

Meeting of May 16, 2025: 5 items on KRYSTAL BIOTECH INC.’s Form 8-K, filed May 19, 2025: 2 approved · 3 passed (calculated).

Dissent

Notable dissent: 1 director (17.2% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore KRYSTAL BIOTECH INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by KRYSTAL BIOTECH INC.

These tallies are KRYSTAL BIOTECH INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 19, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

KRYSTAL BIOTECH INC. — official shareholder meeting results, meeting held May 16, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Daniel S. Janney 19,838,511---- 4,134,7553,770,846 83%Passed (calculated)—
Elect Director: Dino A. Rossi 23,336,879---- 636,3873,770,846 97%Passed (calculated)—
Elect Director: E. Rand Sutherland, M.D. 23,337,104---- 636,1623,770,846 97%Passed (calculated)—
2. Ratification of Appointment of Independent Registered Public Accounting Firm 27,723,99714,7615,354 ---- 99.9%Approved—
3. Non-Binding, Advisory Vote on Named Executive Officer Compensation 22,543,6831,423,4376,146 --3,770,846 94%Approved—

Source: KRYSTAL BIOTECH INC., Form 8-K, filed with the SEC on May 19, 2025 — read the filing on EDGAR.

How asset managers voted at the KRYSTAL BIOTECH INC. 2024-2025 meeting

306 asset managers disclosed a vote on at least one KRYSTAL BIOTECH INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Daniel S. Janney

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

83% Majority: yes · of votes cast

FOR 83%WITHHELD
FOR: 19,838,511WITHHELD: 4,134,755
Details: description as filed, official tally, votes by 102 asset managers

Description as filed by funds: Election of Class II Directors: Daniel S. Janney

KRYSTAL BIOTECH INC.’s own tally for this item (“Elect Director: Daniel S. Janney”): 19,838,511 for, 4,134,755 withheld, per its Form 8-K filed May 19, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 83% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 102 asset managers below reported 11,801,640 for, 1,432,937 withheld, 153,424 abstained.

FOR
FOR: 11,801,640ABSTAIN: 153,424WITHHOLD: 1,432,937
Largest asset managers voting on “Election of Class II Directors: Daniel S. Janney” at KRYSTAL BIOTECH INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity3,666,7460 00For
Vanguard2,766,1740 51,062For
BlackRock2,322,3140 00For
Capital Group887,1040 00For
State Street617,8340 018,079For
T. Rowe Price361,6680 0130,867Mixed
Dimensional00 0392,584Withhold
Manager Directed Portfolios302,9410 00For
Charles Schwab226,5410 00For
TIAA190,3000 00For
Invesco00 0123,297Withhold
MUTUAL FUND SERIES TRUST95,7810 01,588For
Lord Abbett00 086,545Withhold
Jackson National00 86,4200Abstain
Equitable43,1460 029,460Mixed
NEW ECONOMY FUND63,9270 00For
Aberdeen00 057,033Withhold
Columbia Threadneedle00 053,792Withhold
Victory Capital00 053,301Withhold
OBERWEIS FUNDS00 046,800Withhold
John Hancock27,8020 18,1020Mixed
Voya00 043,785Withhold
QUANTITATIVE MASTER SERIES LLC42,2740 00For
Lincoln Financial26,3460 013,590Mixed
Nuveen36,9530 00For

Showing the 25 largest of 102 asset managers. All 102 are in the interactive database (link above).

Elect Director: Dino A. Rossi

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 23,336,879WITHHELD: 636,387
Details: description as filed, official tally, votes by 102 asset managers

Description as filed by funds: Election of Class II Directors: Dino A. Rossi

KRYSTAL BIOTECH INC.’s own tally for this item (“Elect Director: Dino A. Rossi”): 23,336,879 for, 636,387 withheld, per its Form 8-K filed May 19, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 102 asset managers below reported 12,921,619 for, 450,310 withheld, 16,072 abstained.

FOR
FOR: 12,921,619ABSTAIN: 16,072WITHHOLD: 450,310
Largest asset managers voting on “Election of Class II Directors: Dino A. Rossi” at KRYSTAL BIOTECH INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity3,666,7460 00For
Vanguard2,767,2400 10For
BlackRock2,322,3140 00For
Capital Group887,1040 00For
State Street635,9130 00For
T. Rowe Price492,5350 00For
Dimensional00 0392,584Withhold
Manager Directed Portfolios302,9410 00For
Charles Schwab226,5410 00For
TIAA190,3000 00For
Invesco123,2970 00For
MUTUAL FUND SERIES TRUST97,3690 00For
Lord Abbett86,5450 00For
Jackson National80,3050 6,1150Mixed
Equitable43,1460 029,460Mixed
NEW ECONOMY FUND63,9270 00For
Aberdeen57,0330 00For
Columbia Threadneedle53,7920 00For
Victory Capital53,3010 00For
OBERWEIS FUNDS46,8000 00For
John Hancock36,6120 9,2920Mixed
Voya43,7850 00For
QUANTITATIVE MASTER SERIES LLC42,2740 00For
Lincoln Financial37,4000 02,536Mixed
Nuveen36,9530 00For

Showing the 25 largest of 102 asset managers. All 102 are in the interactive database (link above).

Elect Director: E. Rand Sutherland, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 23,337,104WITHHELD: 636,162
Details: description as filed, official tally, votes by 102 asset managers

Description as filed by funds: Election of Class II Directors: E. Rand Sutherland

KRYSTAL BIOTECH INC.’s own tally for this item (“Elect Director: E. Rand Sutherland, M.D.”): 23,337,104 for, 636,162 withheld, per its Form 8-K filed May 19, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 102 asset managers below reported 12,939,819 for, 432,110 withheld, 16,072 abstained.

FOR
FOR: 12,939,819ABSTAIN: 16,072WITHHOLD: 432,110
Largest asset managers voting on “Election of Class II Directors: E. Rand Sutherland” at KRYSTAL BIOTECH INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity3,666,7460 00For
Vanguard2,767,2400 10For
BlackRock2,322,3140 00For
Capital Group887,1040 00For
State Street635,9130 00For
T. Rowe Price492,5350 00For
Dimensional00 0392,584Withhold
Manager Directed Portfolios302,9410 00For
Charles Schwab226,5410 00For
TIAA190,3000 00For
Invesco123,2970 00For
MUTUAL FUND SERIES TRUST97,3690 00For
Lord Abbett86,5450 00For
Jackson National80,3050 6,1150Mixed
Equitable43,1460 029,460Mixed
NEW ECONOMY FUND63,9270 00For
Aberdeen57,0330 00For
Columbia Threadneedle53,7920 00For
Victory Capital53,3010 00For
OBERWEIS FUNDS46,8000 00For
John Hancock36,6120 9,2920Mixed
Voya43,7850 00For
QUANTITATIVE MASTER SERIES LLC42,2740 00For
Lincoln Financial37,4000 02,536Mixed
Nuveen36,9530 00For

Showing the 25 largest of 102 asset managers. All 102 are in the interactive database (link above).

Non-Binding, Advisory Vote on Named Executive Officer Compensation

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 11 wordings of this item as funds reported it.

94% Approved · of votes cast

FOR 94%
FOR: 22,543,683AGAINST: 1,423,437

Prior year: 96.2% for (May 21, 2024 meeting) ▼ 2.2 pts

Details: description as filed, official tally, votes by 306 asset managers

Description as filed by funds: Approval of the compensation of the Company's named executive officers, on a non-binding, advisory basis.

KRYSTAL BIOTECH INC.’s own tally for this item (“3. Non-Binding, Advisory Vote on Named Executive Officer Compensation”): 22,543,683 for, 1,423,437 against — passed, per its Form 8-K filed May 19, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Three: Non-Binding, Advisory Vote on Named Executive Officer Compensation The Company's stockholders approved, on an advisory (non-binding) basis, the compensation of the Company's named executive officers for the fiscal year ended December 31, 2024, as disclosed in the Company's proxy sta…”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 103 asset managers voting on “Approval of the compensation of the Company's named executive officers, on a non-binding, advisory basis.” at KRYSTAL BIOTECH INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity3,666,7460 00For
Vanguard2,767,2392 00For
BlackRock2,322,3140 00For
Capital Group0887,104 00Against
State Street620,37615,537 00For
T. Rowe Price492,5350 00For
Dimensional392,5840 00For
Manager Directed Portfolios302,9410 00For
Charles Schwab226,5410 00For
TIAA190,3000 00For
Invesco123,2970 00For
MUTUAL FUND SERIES TRUST97,3690 00For
Lord Abbett86,5450 00For
Jackson National86,4200 00For
Equitable72,6060 00For
NEW ECONOMY FUND063,927 00Against
Aberdeen57,0330 00For
Columbia Threadneedle053,792 00Against
Victory Capital53,3010 00For
OBERWEIS FUNDS46,8000 00For
John Hancock45,9040 00For
Voya43,7850 00For
QUANTITATIVE MASTER SERIES LLC42,2740 00For
Lincoln Financial39,9360 00For
Nuveen36,9530 00For

Fund voting reports, all 103 managers: 12,332,623 for, 1,042,579 against, 3,400 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 232 asset managers voting on “Approval of the compensation of the Company's named executive officers, on a non-binding, advisory basis.” at KRYSTAL BIOTECH INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity4,284,4810 00For
Avoro Capital Advisors LLC2,201,9280 00For
State Street1,104,50615,616 00For
Capital Group0954,468 00Against
Redmile Group, LLC737,6750 00For
Frazier Life Sciences Management, L.P.688,4600 00For
T. Rowe Price659,1510 00For
BlackRock613,18510,371 00For
GEODE CAPITAL MANAGEMENT, LLC607,3860 00For
Hood River Capital Management LLC487,1910 00For
BRAIDWELL LP288,1230 00For
Charles Schwab250,2580 00For
Soleus Capital Management, L.P.235,3960 00For
Nuveen231,2050 00For
Woodline Partners LP218,0430 00For
Invesco174,8620 00For
Northern Trust159,2770 00For
MELLON INVESTMENTS Corp132,5710 00For
PRINCIPAL GLOBAL INVESTORS126,5070 00For
LORD, ABBETT & CO. LLC99,3500 00For
S Squared Technology, LLC99,2150 00For
Victory Capital96,1950 00For
TimesSquare Capital Management, LLC94,8960 00For
JPMorgan92,4370 00For
Vanguard90,5710 00For

Institutional-manager reports, all 232 managers: 15,047,908 for, 1,282,446 against, 18,200 withheld, 14 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Appointment of Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 27,723,997AGAINST: 14,761

Prior year: 100.0% for (May 21, 2024 meeting) unchanged

Details: description as filed, official tally, votes by 104 asset managers

Description as filed by funds: To ratify the appointment of KPMG LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025.

KRYSTAL BIOTECH INC.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm”): 27,723,997 for, 14,761 against — passed, per its Form 8-K filed May 19, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 104 asset managers below reported 13,377,911 for, 11,054 against, 3,400 abstained.

FOR
FOR: 13,377,911AGAINST: 11,054ABSTAIN: 3,400
Largest asset managers voting on “To ratify the appointment of KPMG LLP as our independent registered public accounting firm for our fiscal year” at KRYSTAL BIOTECH INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity3,666,7460 00For
Vanguard2,767,2410 00For
BlackRock2,322,3140 00For
Capital Group887,1040 00For
State Street635,9130 00For
T. Rowe Price492,5350 00For
Dimensional392,5840 00For
Manager Directed Portfolios302,9410 00For
Charles Schwab226,5410 00For
TIAA190,3000 00For
Invesco123,2970 00For
MUTUAL FUND SERIES TRUST97,3690 00For
Lord Abbett86,5450 00For
Jackson National86,4200 00For
Equitable72,6060 00For
NEW ECONOMY FUND63,9270 00For
Aberdeen57,0330 00For
Columbia Threadneedle53,7920 00For
Victory Capital53,3010 00For
OBERWEIS FUNDS46,8000 00For
John Hancock45,9040 00For
Voya43,7850 00For
QUANTITATIVE MASTER SERIES LLC42,2740 00For
Lincoln Financial39,9360 00For
Nuveen36,9530 00For

Showing the 25 largest of 104 asset managers. All 104 are in the interactive database (link above).

Largest KRYSTAL BIOTECH INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 28,899,000 shares outstanding at the time of that meeting.

Fund voting reports: top KRYSTAL BIOTECH INC. shareholders by shares voted on “Approval of the compensation of the Company's named executive officers, on a non-binding…”, 2024-2025
#Asset manager % of shares outstanding
1Fidelity 12.69%
2Vanguard 9.58%
3BlackRock 8.04%
4Capital Group 3.07%
5State Street 2.20%
6T. Rowe Price 1.70%
7Dimensional 1.36%
8Manager Directed Portfolios 1.05%
9Charles Schwab 0.78%
10TIAA 0.66%
Institutional-manager reports: top KRYSTAL BIOTECH INC. shareholders by shares voted on “Approval of the compensation of the Company's named executive officers, on a non-binding…”, 2024-2025
#Asset manager % of shares outstanding
1Fidelity 14.83%
2Avoro Capital Advisors LLC 7.62%
3State Street 3.88%
4Capital Group 3.30%
5Redmile Group, LLC 2.55%
6Frazier Life Sciences Management, L.P. 2.38%
7T. Rowe Price 2.28%
8BlackRock 2.16%
9GEODE CAPITAL MANAGEMENT, LLC 2.10%
10Hood River Capital Management LLC 1.69%

Reported KRYSTAL BIOTECH INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

KRYSTAL BIOTECH INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
FMR (Fidelity)4,320,832 14.95%Form 13F, quarter ended March 31, 2025
FMR LLC4,292,881 14.85%Proxy statement (DEF 14A), proxy filed April 3, 2025
BlackRock3,943,165 13.64%Form 13F, quarter ended March 31, 2025
Krish S. Krishnan3,388,283 11.72%Schedule 13G, filed May 4, 2026
Vanguard Group2,825,282 9.78%Form 13F, quarter ended March 31, 2025
Avoro Capital Advisors LLC2,565,555 8.88%Proxy statement (DEF 14A), proxy filed April 3, 2025
Suma M. Krishnan1,698,810 5.88%Proxy statement (DEF 14A), proxy filed April 3, 2025
STATE STREET CORPORATION1,278,975 4.43%Schedule 13G, filed February 5, 2025
Dimensional Fund Advisors533,919 1.85%Form 13F, quarter ended March 31, 2025
T. Rowe Price410,861 1.42%Form 13F, quarter ended March 31, 2025

Percentages above are of 28,899,000 shares outstanding, as reported by KRYSTAL BIOTECH INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At KRYSTAL BIOTECH INC.'s shareholder meeting held May 16, 2025, in the 2024-2025 proxy season, 306 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 2,142 separate fund positions. On the most widely held item on that ballot — Approval of the compensation of the Company's named executive officers, on a non-binding… — KRYSTAL BIOTECH INC.'s filing reports the proposal as approved, with 94% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: KRYSTAL BIOTECH INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 19, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from KRYSTAL BIOTECH INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

KRYSTAL BIOTECH INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “KRYSTAL BIOTECH (KRYS) 2025 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/krystal-biotech-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.